Royal Bank Of Canada Immunity Bio, Inc. Transaction History
Royal Bank Of Canada
- $471 Billion
- Q3 2024
A detailed history of Royal Bank Of Canada transactions in Immunity Bio, Inc. stock. As of the latest transaction made, Royal Bank Of Canada holds 127,536 shares of IBRX stock, worth $572,636. This represents 0.0% of its overall portfolio holdings.
Number of Shares
127,536
Previous 470,194
72.88%
Holding current value
$572,636
Previous $2.97 Million
84.08%
% of portfolio
0.0%
Previous 0.0%
Shares
15 transactions
Others Institutions Holding IBRX
# of Institutions
202Shares Held
70MCall Options Held
1.68MPut Options Held
1.31M-
Vanguard Group Inc Valley Forge, PA16.9MShares$75.9 Million0.0% of portfolio
-
Black Rock Inc. New York, NY11.4MShares$51.3 Million0.0% of portfolio
-
State Street Corp Boston, MA8.65MShares$38.9 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA3.85MShares$17.3 Million0.0% of portfolio
-
Morgan Stanley New York, NY2.25MShares$10.1 Million0.0% of portfolio
About ImmunityBio, Inc.
- Ticker IBRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 400,304,000
- Market Cap $1.8B
- Description
- ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The com...